Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Apixaban (Primary) ; Warfarin (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 12 Oct 2017 Planned number of patients changed from 114131 to 300000.
- 12 Oct 2017 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 12 Oct 2017 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.